MIRA Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - General · United States

Last price 0.5716 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 24.02M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dem...